Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic Sells 2,151 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 2,151 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $16,670.25. Following the completion of the sale, the chief technology officer now directly owns 209,456 shares in the company, valued at $1,623,284. This trade represents a 1.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA opened at $7.65 on Wednesday. The firm has a market cap of $382.12 million, a PE ratio of -4.42 and a beta of 0.29. The firm’s 50 day simple moving average is $8.07 and its 200-day simple moving average is $8.76. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors have recently modified their holdings of the stock. Barclays PLC increased its position in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares during the period. State Street Corp boosted its stake in shares of Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after purchasing an additional 39,379 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Aura Biosciences during the third quarter valued at approximately $1,037,000. Finally, Franklin Resources Inc. boosted its stake in shares of Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after purchasing an additional 215,597 shares in the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on AURA. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Aura Biosciences has a consensus rating of “Buy” and an average price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.